Company Overview of NexGenix Pharmaceuticals Holdings, Inc.
NexGenix Pharmaceuticals Holdings, Inc., a biotechnology company, engages in the discovery and development of therapies for oncology and nervous system diseases. It offers Hsp90 inhibitor, a therapy for oncology, neurofibromatosis, and neurodegenerative disorders. The company also develops a non-surgical intralesional treatment for dermal neurofibromas. Its products also are used in the treatment of glioblastoma and Parkinson's disease. NexGenix Pharmaceuticals Holdings, Inc. was founded in 2003 and is based in New York, New York.
152 West 57th Street
New York, NY 10019
Founded in 2003
Key Executives for NexGenix Pharmaceuticals Holdings, Inc.
Similar Private Companies By Industry
|20n Labs, Inc.||United States|
|23andMe, Inc.||United States|
|2C Tech Corporation, Inc.||United States|
|3-V Biosciences, Inc.||United States|
|3Bar Biologics Inc.||United States|
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.
Most Searched Private Companies
|Company Name||Geographic Region|
|Lawyers Committee for Civil Rights Under Law||United States|
|The Advertising Council, Inc.||United States|
|Tax Management Inc||United States|
|John F. Kennedy Center For The Performing Arts||United States|
|NYC2012, Inc.||United States|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.
To contact NexGenix Pharmaceuticals Holdings, Inc., please visit www.nexgenixpharm.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.